• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

First Reported U.S. Cases of Tinea Caused by Trichophyton indotineae — New York City, December 2021–March 2023

Mary Wilson

Well-known member
May 12, 2023

DOI: http://dx.doi.org/10.15585/mmwr.mm7219a4

Caplan AS, Chaturvedi S, Zhu Y, et al.

Tinea is a common, highly contagious, superficial infection of the skin, hair, or nails caused by dermatophyte molds.* During the past decade, an epidemic of severe, antifungal-resistant tinea has emerged in South Asia because of the rapid spread of Trichophyton indotineae,[SUP]†[/SUP] a novel dermatophyte species; the epidemic has likely been driven by misuse and overuse of topical antifungals and corticosteroids[SUP]§[/SUP] (1,2). T. indotineae infections are highly transmissible and characterized by widespread, inflamed, pruritic plaques on the body (tinea corporis), the crural fold, pubic region, and adjacent thigh (tinea cruris), or the face (tinea faciei) (1). T. indotineaeisolates are frequently resistant to terbinafine, a mainstay of tinea treatment (1,3). T. indotineaeinfections have been reported throughout Asia and in Europe and Canada but have not previously been described in the United States (3).

On February 28, 2023, a New York City dermatologist notified public health officials of two patients who had severe tinea that did not improve with oral terbinafine treatment, raising concern for potential T. indotineae infection; these patients shared no epidemiologic links. Skin culture isolates from each patient were previously identified by a clinical laboratory as Trichophyton mentagrophytes and were subsequently forwarded to the Wadsworth Center, New York State Department of Health, for further review and analysis. Sanger sequencing of the internal transcribed spacer region of the ribosomal gene, followed by phylogenetic analysis performed during March 2023, identified the isolates as T. indotineae (Supplementary Figure; https://stacks.cdc.gov/view/cdc/127678). Activity related to this investigation was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. ...

FIGURE. Lesions occurring on two patients with first reported U.S. cases of tinea caused by Trichophyton indotineae, on patient A’s neck, abdomen, and buttocks (A–C)* and on patient B’s thighs[SUP]†[/SUP] (D) — New York City, December 2021–March 2023

mm7219a4-F-medium.gif

Photos/Lu Yin (A–C) and Vignesh Ramachandran (D). Used with patients’ permission.

* At initial dermatology evaluation, patient A had large, annular, scaly, and pruritic erythematous plaques of the neck, abdomen, groin, and buttocks.

[SUP]†[/SUP] At initial dermatology evaluation, patient B had widespread, discrete, scaly, annular, pruritic plaques affecting the thighs and buttocks.

​​​​​​​https://www.cdc.gov/mmwr/volumes/72/wr/mm7219a4.htm#suggestedcitation

 
Back
Top